New Drug Shows Promise Against Pancreatic Cancer

Share f X WA in

The drug, daraxonrasib, was evaluated in combination with chemotherapy in research presented in Barcelona. According to the findings, patients receiving the combination treatment had a better one-year survival rate than those receiving standard treatment.

The study found that 60.7 per cent of participants experienced a reduction in tumour size or complete tumour disappearance. In 8.2 per cent of patients, tumours became completely undetectable.

Tumour growth halted in most trial participants

According to the research, 90.2 per cent of the 61 participants experienced no further tumour growth during the follow-up period of approximately 18 months.

The findings indicate that the combination of daraxonrasib and chemotherapy may offer a potential treatment option for patients with advanced pancreatic cancer.

Drug targets mutated KRAS gene

Daraxonrasib targets a mutated form of the KRAS gene, which is found in more than 90 per cent of pancreatic cancer tumours.

Researchers described the results as encouraging, particularly for patients whose tumours responded significantly to the treatment.

However, experts cautioned that the findings do not establish the drug as a definitive cure for pancreatic cancer. Further research will be needed to determine its effectiveness and long-term benefits.

Follow The Public Purview on WhatsApp